NCT00507091View on ClinicalTrials.gov

Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

May 31, 2006

Study Completion Date

June 30, 2008

Conditions
MetastaticColorectalAdenocarcinoma
Interventions
DRUG

ZD6474 (vandetanib) 100mg

once daily oral tablet

DRUG

Irinotecan

intravenous infusion

DRUG

5-Fluorouracil

intravenous infusion

DRUG

Leucovorin

intravenous infusion

DRUG

ZD6474 (vandetanib) 300mg

once daily oral tablet

Trial Locations (3)

Unknown

Research Site, Ghent

Research Site, Belfast

Research Site, Manchester

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00507091 - Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination | Biotech Hunter | Biotech Hunter